430 results on '"Mano, Max"'
Search Results
2. Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial
3. Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
4. Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil
5. Gene expression signatures in early breast cancer: Better together with clinicopathological features
6. Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?
7. Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
8. Câncer de mama: a visão do mastologista para residentes em Oncologia
9. Câncer de mama: a visão do oncologista para residentes em Mastologia
10. Oncologia de Precisão no câncer de mama
11. Tratamento sistêmico neoadjuvante do câncer de mama
12. Tumores da Mama
13. Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads
14. The impact on clinical outcomes of post-operative radiation therapy delay after neoadjuvant chemotherapy in patients with breast cancer: A multicentric international study
15. The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients.
16. Neoadjuvant Therapies
17. Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads
18. More on treatment de-escalation, biomarkers of response in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: long-term outcomes and translational research findings of the PREDIX HER2 trial
19. Circulating microRNAs as potential biomarkers in triple-negative breast cancer: a translational research study of the NACATRINE trial
20. The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)
21. Tumores da Mama
22. Tratamento neoadjuvante do câncer de mama
23. Câncer de mama: a visão do oncologista para residentes em Mastologia
24. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
25. Patterns of post-operative irradiation in breast cancer patients submitted to neoadjuvant chemotherapy
26. Integrating Adjuvant Radiation with Post-Neoadjuvant Therapies in Early Breast Cancer
27. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial
28. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer
29. Takotsubo syndrome induced by brachytherapy in a patient with endocervical adenocarcinoma
30. Challenging Outlook of Caring for Adolescents and Young Adults With Cancer in Brazil: Results of a Nationwide Survey
31. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
32. Circulating microRNAs as potential biomarkers in triple-negative breast cancer: a translational research study of the NACATRINE trial.
33. Results of a survey study on health professionals' perceptions of tumor boards in Brazil
34. Supplementary Table S2 from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
35. Supplementary Figure S2 from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
36. Data from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
37. Abstract P4-03-36: Determinants of severe COVID-19 infection in Patients with Breast Cancer from a Community Oncology Practice in Brazil
38. Effects of locoregional radiotherapy in patients with metastatic breast cancer
39. A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
40. Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
41. Tumores da Mama
42. If you can't kill the beast, tame it: Tips for surviving WhatsApp® in medical practice
43. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
44. Borderline indications for ovarian suppression: addressing uncertainties with patients
45. If you can’t kill the beast, tame it: Tips for surviving WhatsApp® in medical practice
46. Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in Brazil
47. Chemoradiation for Rectal Cancer
48. Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
49. Biological therapies in breast cancer: Common toxicities and management strategies
50. Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.